Form 8-K - Current report:
SEC Accession No. 0000950170-24-046481
Filing Date
2024-04-22
Accepted
2024-04-22 16:55:14
Documents
12
Period of Report
2024-04-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kalv-20240418.htm   iXBRL 8-K 44628
2 EX-99.1 kalv-ex99_1.htm EX-99.1 13530
  Complete submission text file 0000950170-24-046481.txt   176498

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kalv-20240418.xsd EX-101.SCH 24861
15 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20240418_htm.xml XML 4718
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 24861818
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)